Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.
2.

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.

Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K.

Treat Respir Med. 2004;3(3):173-81.

PMID:
15219176
3.

Case-control study of salmeterol and near-fatal attacks of asthma.

Williams C, Crossland L, Finnerty J, Crane J, Holgate S, Pearce N, Beasley R.

Thorax. 1998 Jan;53(1):7-13.

4.

Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.

Cates CJ, Wieland LS, Oleszczuk M, Kew KM.

Cochrane Database Syst Rev. 2014 Feb 6;(2):CD010314. doi: 10.1002/14651858.CD010314.pub2. Review.

PMID:
24504983
5.

Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease.

Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB.

Ann Intern Med. 2008 Sep 16;149(6):380-90.

PMID:
18794557
6.

Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.

Jara M, Lanes SF, Wentworth C 3rd, May C, Kesten S.

Drug Saf. 2007;30(12):1151-60.

PMID:
18035867
7.

Salmeterol versus theophylline in the treatment of asthma.

Pollard SJ, Spector SL, Yancey SW, Cox FM, Emmett A.

Ann Allergy Asthma Immunol. 1997 May;78(5):457-64.

PMID:
9164358
8.

Characteristics of users of inhaled long-acting beta 2-agonists in a southern European population.

Castellsague J, Garcia-Rodríguez LA, Pérez-Gutthann S, Agostinis L, Cattaruzi C, Troncon MG.

Respir Med. 1999 Oct;93(10):709-14.

PMID:
10581659
9.

Efficacy of salmeterol xinafoate in the treatment of COPD.

Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH.

Chest. 1999 Apr;115(4):957-65.

PMID:
10208192
10.
13.

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.

Cates CJ, Lasserson TJ, Jaeschke R.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006922. doi: 10.1002/14651858.CD006922.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD006922.

PMID:
19588410
14.

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.

Mann RD, Kubota K, Pearce G, Wilton L.

J Clin Epidemiol. 1996 Feb;49(2):247-50.

PMID:
8606326
15.

Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.

Cates CJ, Jaeschke R, Schmidt S, Ferrer M.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD006922. doi: 10.1002/14651858.CD006922.pub3. Review.

PMID:
23543548
17.
18.

Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events.

Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S.

Ann Intern Med. 2008 Jul 1;149(1):33-42. Epub 2008 Jun 3.

PMID:
18523132
19.

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.

D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI.

JAMA. 1994 May 11;271(18):1412-6.

PMID:
7909853
20.

Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.

Rosenthal RR, Busse WW, Kemp JP, Baker JW, Kalberg C, Emmett A, Rickard KA.

Chest. 1999 Sep;116(3):595-602.

PMID:
10492259

Supplemental Content

Support Center